Skip to content

Evaluation of EndoRefix Endovascular Delivery System and Staple

Safety Data Collection for Delivery System and Use of Staple in Endovascular Procedures

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00668681
Acronym
EndoRefix
Enrollment
0
Registered
2008-04-29
Start date
2008-04-30
Completion date
2009-02-28
Last updated
2012-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AAA Graft Implant for Primary Aneurysm Treatment, AAA Graft Repair to Extend Life of Implant

Keywords

Abdominal Aortic Aneurysm

Brief summary

This study is intended to provide data to verify safe delivery of a staple previously intended for use in open surgical procedures. A newly modified delivery system will provide endovascular access for implantation of a staple during endovascular graft procedures.

Interventions

DEVICEEndoRefix

Sponsors

Lombard Medical
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male or female \>21 years of age 2. Undergoing endovascular stent grafting for AAA repair 3. Post endovascular stent grafting where stent stabilization is necessary due to stent fixation failure and/or persistent endoleak.

Exclusion criteria

1. Pregnant 2. Religious, cultural or other objection to the receipt of blood, or blood products. 3. Unwilling to comply with follow-up schedule 4. Unwillingness, or inability to provide informed consent to both trila and procedure 5. Ruptured Aneurysm 6. Area where staple is to be placed has significant loose thrombus associated with it 7. Acute or chronic aortic dissection or mycotoc aneurysm 8. Allergy to device materials 9. Allergy to or intolerance to use of contrast media or cannot be exposed to suitable remedial treatment such as steroids and/or diphenhydramine. 10. Clinically and morbidly obese such that imaging would be severely adversely affected. 11. Uncorrectable bleeding abnormality 12. Inflammatory aneurysm 13. Connective tissue disease (e.g., Marfans syndrome, Ehlers Danlos syndrome) 14. Patients with PTFE grafts 15. Patients with investigational grafts (i.e., those grafts that are not FDA approved)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026